NCT03435536

Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer

Influence of Pancreatic Adenocarcinoma Excision Surgery on Peripheral and Portal Circulating Tumor DNA: Prospective Exploratory Pilot Study.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: University Hospital, Toulouse · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Pancreatic cancer represents the fourth cause of death by cancer in western countries. The only curative treatment is surgery but this one is possible only in 10 to 15 % of cases. To date, there are few biomarkers in circulating blood as prognostic or diagnostic markers in pancreatic cancer. The purpose of this study is to determine if the pancreatic tumor mobilization during its resection impacts the quantity of circulating tumor DNA in peripheral and portal blood.

Detailed description

The investigators will analyze if the tumor mobilization increases circulating DNA rate in peripheral and portal blood. Moreover, circulating tumor DNA will be measured during 12 months after surgery in peripheral blood. They will use a gene mutation detection technique called Next Generation Sequencing (NGS) which is more specific than a simple Polymerase Chain Reaction (PCR).

Conditions

• Resectable Pancreatic Cancer

Interventions

Type	Name	Description
OTHER	Blood samples	Blood samples will be taken to analyze the circulating tumor DNA rate by NGS

Timeline

• Start date: 2018-02-26
• Primary completion: 2022-06-20
• Completion: 2022-06-20
• First posted: 2018-02-19
• Last updated: 2025-11-28

Locations

1 site across 1 country: France